Entrada Therapeutics annual revenue
2022
2023
2024
2025
Entrada Therapeutics Revenue Growth & History (TRDA)
Entrada Therapeutics reported $25.4M in revenue for fiscal 2025, a decrease of 87.94% from the previous fiscal year.
View full Entrada Therapeutics company overviewEntrada Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $25.4M | −$185.4M | −87.94% |
| 2024 | 2024-12-31 | $210.8M | $81.8M | +63.38% |
| 2023 | 2023-12-31 | $129.0M | $129.0M | — |
| 2022 | 2022-12-31 | $0 | — | — |
Entrada Therapeutics quarterly revenue
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $898,000 | −$1.1M | −53.95% |
| Q1 2026 | 2026-03-31 | $875,000 | −$19.7M | −95.74% |
| Q4 2025 | 2025-12-31 | $1.3M | −$36.1M | −96.53% |
| Q3 2025 | 2025-09-30 | $1.6M | −$18.0M | −91.75% |
| Q2 2025 | 2025-06-30 | $1.9M | −$92.7M | −97.94% |
| Q1 2025 | 2025-03-31 | $20.6M | −$38.6M | −65.23% |
| Q4 2024 | 2024-12-31 | $37.4M | −$4.5M | −10.63% |
| Q3 2024 | 2024-09-30 | $19.6M | −$24.2M | −55.25% |
| Q2 2024 | 2024-06-30 | $94.7M | $76.5M | +421.16% |
| Q1 2024 | 2024-03-31 | $59.1M | $33.9M | +134.05% |
| Q4 2023 | 2023-12-31 | $41.8M | — | — |
| Q3 2023 | 2023-09-30 | $43.7M | $43.7M | — |
| Q2 2023 | 2023-06-30 | $18.2M | $18.2M | — |
| Q1 2023 | 2023-03-31 | $25.3M | $25.3M | — |
| Q3 2022 | 2022-09-30 | $0 | — | — |
| Q2 2022 | 2022-06-30 | $0 | — | — |
| Q1 2022 | 2022-03-31 | $0 | — | — |
Entrada Therapeutics revenue growth trends
Entrada Therapeutics's latest reported quarter, Q2 2026, generated $898,000 in revenue, a decrease of 53.95% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Entrada Therapeutics source filings ↗